ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2018, Vol. 27 ›› Issue (2): 161-167.DOI: 10.3969/j.issn.1006-298X.2018.02.014

• 论文 • 上一篇    下一篇

2017年美国风湿病协会糖皮质激素性骨质疏松症预防与治疗指南

  

  • 出版日期:2018-04-28 发布日期:2018-05-02

2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoidinduced osteoporosis

  • Online:2018-04-28 Published:2018-05-02

摘要:

长期应用糖皮质激素(GCs)导致的糖皮质激素性骨质疏松症(GIOP)临床危害大,是重要的公共健康问题,缺乏干预治疗的评估证据。美国风湿病协会(ACR)制定的GIOP防治指南目前已更新到第三版。本次修订的指南运用多种方式进行证据等级评价,对普通成年人和特殊人群(如儿童、器官移植患者、育龄女性及大剂量GCs治疗患者)的GIOP骨折风险进行评估,并分析治疗药物的利弊,为临床医师和患者在治疗决策上提供指导,推荐优化治疗,以期获得最大效益。

关键词: 糖皮质激素性骨质疏松症, 骨折风险, 评估, 预防和治疗, 指南

Abstract:

Longterm use of glucocorticoids (GCs) may leads to glucocorticoidinduced osteoporosis (GIOP), which is an important public health problem and lacking of assessment evidence for interventions and treatment. The GIOP guidelines developed by the American College of Rheumatology (ACR) have now been updated to the third edition. This revised guidelines use a variety of measurement to rating the evidence, assessing the risk of GIOP fractures in adults and in special populations (eg, children, organ transplant recipients, women of childbearing potential, and people receiving highdose GC treatment), and to analyze the benefits and harms of treatment, providing guidance in the treatment decisionmaking for clinicians and patients, recommending optimal treatment to get the maximum benefit.

Key words: glucocorticoid-induced osteoporosis, fracture risk, assessment, prevention and treatment, guideline